Results 1 to 10 of about 5,280 (145)

PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy [PDF]

open access: yesFrontiers in Immunology
Poly-ADP-ribosylation (PARylation) is a post-translational modification in which ADP-ribose is added to substrate proteins. PARylation is mediated by a superfamily of ADP-ribosyl transferases known as PARPs and influences a wide range of cellular ...
Yoshinori Matsumoto, Jun Wada
exaly   +4 more sources

PARP1-mediated PARylation activity is essential for oligodendroglial differentiation and CNS myelination [PDF]

open access: yesCell Reports, 2021
Summary: The function of poly(ADP-ribosyl) polymerase 1 (PARP1) in myelination and remyelination of the central nervous system (CNS) remains enigmatic.
Bokyung Kim   +2 more
exaly   +5 more sources

ADP-ribosylation: An emerging regulator of the epigenome. [PDF]

open access: yesMol Oncol
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Camacho CV, Liu C, Kraus WL.
europepmc   +2 more sources

ROS-ATM-CBP axis-mediated PARP1 lactylation aggravates doxorubicin-induced cardiotoxicity. [PDF]

open access: yesClin Transl Med
ROS function as signalling molecules to promote CBP‐mediated PARP1 lactylation in an ATM dependent manner, which induces PARP1 PARylation and ultimate cell apoptosis. CBP and SIRT1 as specific lactyltransferase and delactylase of PARP1. Lactylation of PARP1 depends on the LDHA activity and lactate production.
Wang W, Sun Y.
europepmc   +2 more sources

PARG inhibition reduces ssDNA levels and limits RPA loading upon replication fork collapse [PDF]

open access: yesEMBO Reports
Poly(ADP-ribosyl)ation (PARylation) is a transient post-translational modification catalyzed by PARP enzymes and reversed by PARG. PARG inhibition causes sustained PARylation and is being explored as an anticancer strategy, but its cellular consequences ...
Alexandra Mihuț   +8 more
doaj   +2 more sources

PARylation-centric crosstalk: orchestrating immune evasion and multidrug resistance in ovarian cancer [PDF]

open access: yesFrontiers in Immunology
Post-translational modifications (PTMs) play pivotal roles in ovarian cancer pathogenesis, with poly(ADP-ribosyl)ation (PARylation) serving as a key regulator of DNA repair, immune evasion, and therapeutic resistance.
Lin Hou   +6 more
doaj   +2 more sources

PARylation in Parkinson’s disease: a bridge between Lewy body formation and neuronal cell death [PDF]

open access: yesCell Death and Disease
Poly-ADP-ribosylation (PARylation), catalyzed by the enzyme PARP1, involves the addition of poly-ADP-ribose polymers (PAR) and has been associated with α-synuclein aggregation in Parkinson’s disease (PD) models.
Claudia Novello   +13 more
doaj   +2 more sources

The Landscape of BRCA1-Associated Post-Translational Modifications. [PDF]

open access: yesCell Biol Int
ABSTRACT The BRCA1‐BARD1 complex is a vital protein that promotes homologous recombination, acting through its E3 ubiquitin ligase activity. Although ubiquitination remains its only confirmed enzymatic function, emerging evidence suggests that the complex influences a broad range of post‐translational modifications (PTMs), including methylation ...
Waduge NH, Xiao J, Davis GM.
europepmc   +2 more sources

PARylation promotes acute kidney injury via RACK1 dimerization-mediated HIF-1α degradation

open access: yesActa Pharmaceutica Sinica B
Poly(ADP-ribosyl)ation (PARylation) is a specific form of post-translational modification (PTM) predominantly triggered by the activation of poly-ADP-ribose polymerase 1 (PARP1).
Xiao-Ming Meng, Ju-Tao Yu
exaly   +3 more sources

PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential [PDF]

open access: yesJournal of Translational Medicine
Background ATM deficiency is frequently observed in castration-resistant prostate cancer (CRPC). However, effective therapeutic vulnerabilities associated with this genetic alteration remain poorly defined.
Xuan Zhou   +7 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy